dm+d

Unassigned

New Medicines

Intrahepatic bile duct cancer (cholangiocarcinoma), inoperable or advanced - second-line or greater

Information

New molecular entity
Basilea
Basilea

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes
Yes

Category

Multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions.
Cholangiocarcinoma is a carcinoma arising in any part of the biliary tree from the small intrahepatic bile ducts to the ampulla of Vater at the distal end of the common bile duct. Can also occur (least commonly) as an intrahepatic tumour. The incidence of intrahepatic cholangiocarcinoma is increasing and the incidence is estimated as 0.9-1.3/100,000 for males and 0.4-0.7/100,000 for females. Intrahepatic cholangiocarcinoma accounts for 10-15% of primary liver cancer [1].
Intrahepatic bile duct cancer (cholangiocarcinoma), inoperable or advanced - second-line or greater
Oral